# Clasp Therapeutics

**Canonical:** https://apis.io/providers/clasp-therapeutics/  
**Website:** https://www.clasptx.com/  
**APIs profiled:** 0

Clasp Therapeutics, Inc. is a clinical-stage precision immuno-oncology company developing next-generation T cell engagers (TCEs) built on its proprietary pHLAre platform, which redirects T cells to mutant peptides — such as p53 R175H and mutant KRAS — presented by specific HLA molecules on the surface of tumor cells. The approach is intended to yield off-the-shelf, antibody-like medicines that hit common oncogenic driver mutations with tumor-exclusive specificity. Its lead candidate CLSP-1025 (p53 R175H / HLA-A*02:01) is in the Phase 1 GUARDIAN-101 trial (NCT06778863), and CLSP-5282, a first-in-class KRas-directed TCE, was unveiled at AACR 2026. Founded on research from Bert Vogelstein, Drew Pardoll and colleagues at Johns Hopkins, the company launched in March 2024 with $150 million led by Catalio Capital Management, Third Rock Ventures and Novo Holdings, and operates from Cambridge, Massachusetts and Rockville, Maryland. Clasp Therapeutics is a therapeutics developer and publishes no public API, developer program, SDK, or machine-readable specification.

## Kin Score — 8.9 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 8.9).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 2.2 |
| Commercial Clarity | 10.5 |

Regulatory layer — **Health**: 12.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Clasp Therapeutics Domain Security** — TLSv1.3 · HSTS · DNSSEC · DMARC

## Tags

Company, Biotechnology, Immuno-Oncology, Oncology, Therapeutics, T Cell Engagers, Precision Medicine, Clinical Stage, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/clasp-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.